Table 3.
Antihypertensive medications across study follow-up
| Variable | Lower SBP target (<130mm Hg) | Higher SBP target (130–149mm Hg | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Year 1 | Year 2 | Year 3 | End of study | Baseline | Year 1 | Year 2 | Year 3 | End of study | |
| Mean number ± SD of medications | 1.7±1.2 | 2.4±1.3 | 2.5±1.3 | 2.5±1.3 | 2.4±1.4 | 1.7±1.2 | 1.8±1.4 | 1.8±1.4 | 1.8±1.4 | 1.8±1.4 |
| Diuretic, % | 35.7 | 65.6 | 68.7 | 70.8 | 64.3 | 36.8 | 48.1 | 48.7 | 51.2 | 45.9 |
| Beta-blocker, % | 25.6 | 30.7 | 33.5 | 34.9 | 34.9 | 24.1 | 25.0 | 25.4 | 25.8 | 28.3 |
| Calcium-channel blocker, % | 25.8 | 43.1 | 47.5 | 45.5 | 43.2 | 25.6 | 29.8 | 28.8 | 28.0 | 29.3 |
| ACEi, % | 53.3 | 52.0 | 51.3 | 49.6 | 47.5 | 51.2 | 40.8 | 39.7 | 39.7 | 38.7 |
| ARB, % | 15.3 | 30.6 | 32.6 | 35.0 | 33.6 | 16.6 | 23.5 | 23.5 | 23.9 | 23.9 |
| ACEi or ARB/ diuretic, % | 60.8 | 72.9 | 74.4 | 74.1 | 70.7 | 59.5 | 54.5 | 53.7 | 53.6 | 51.8 |
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure.